Table 2. Univariate and multivariate analysis for factors affecting fever duration during the early transplant period of tandem HDCT/auto-SCT.
| Potential risk factors | Univariate analysis | Multivariate anaylsis | ||||
|---|---|---|---|---|---|---|
| t-score | 95% CI | p-value | t-score | 95% CI | p-value | |
| Second HDCT/auto-SCT (compared to the first) | –1.84 | -1.20~0.04 | 0.067 | –1.79 | -1.17~0.05 | 0.073 |
| Inclusion of TBI and/or thiotepa in HDCT regimen | 3.96 | 0.62~1.85 | <0.001 | 4.00 | 0.63~1.86 | <0.001 |
| Infused CD34+ cells <2 × 106/kg | 1.15 | -0.31~1.18 | 0.249 | 1.07 | -0.33~1.14 | 0.283 |
| Age at transplantation >100 months | -1.09 | -1.3~0.30 | 0.278 | -1.11 | -1.03~0.29 | 0.269 |
HDCT/auto-SCT, high-dose chemotherapy and autologous transplantation; CI, confidence interval; TBI, total body irradiation.